Shenzhen University
Also known as: associate chief physician | Baoan Central Hospital of Shenzhen | Bao'an District Central Hospital of Shenzhen | Baoan District People's Hospital of Shenzhen | Chongqing Red Cross Hospital | Shenzhen Children's Hospital | Shenzheng Baoan Maternity and Child Healthcare Hospital | Shenzhen Luohu Maternal and Child Health Hospital | Shenzhen Maternity & Child Healthcare Hospital | Shenzhen Nanshan Maternity and Child Healthcare Hospital | Shenzhen People Hospital | Shenzhen People's Hospital | Shen Zhen People's Hospital | ShenZhen People's Hospital of Jinan University | Shenzhen Sixth People's Hospital | Shenzhen traditional Chinese medical hospital | Shenzhen traditional Chinese medicine hospital | Shenzhen Traditional Chinese Medicine Hospital | Shenzhen University | Shenzhen University General Hospital | The Third Affiliated Hospital of Shenzhen University | YuLi | Zhenwei Xie
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2006Last known activity
Nov 30, 2025
Timeline
1980s
- Jan 1, 1983
Shenzhen University— Founded
Drugs by trial phase (165 distinct, 120 trials)
Phase 4 (33 own, 0 via acquisition)
Phase 3 (33 own, 0 via acquisition)
Phase 2 (50 own, 0 via acquisition)
Phase 1 (14 own, 0 via acquisition)
Indications
Studied for
- Adrenoleukodystrophy
- Arthritis
- Arthritis, Rheumatoid
- beta-Thalassemia
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Cerebral Infarction
- Cervical Intraepithelial Neoplasia
- Cholangiocarcinoma
- Colorectal Neoplasms
- Communicable Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Digestive System Neoplasms
- Dwarfism, Pituitary
- Embolism
- Endocrine System Diseases
- Endometriosis
- Gastrointestinal Neoplasms
- Herpangina
- Infections
- Intestinal Neoplasms
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphoid
- Leukemia, T-Cell
- Leukodystrophy, Metachromatic
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Nasopharyngeal Carcinoma
- Neoplasms
- Neuroblastoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Pulmonary Embolism
- Recurrence
- Respiratory Tract Infections
- Sarcoma
- Sarcoma, Ewing
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Stroke
- Thalassemia
- Thromboembolism
- Urinary Tract Infections
Recent trials (50)
- NCT07266532Lead sponsorN/ANov 30, 2025
- NCT07194200Lead sponsorPhase 2Oct 1, 2025
- NCT07203599Lead sponsorPhase 1/Phase 2Sep 20, 2025
- NCT07184905Lead sponsorN/ASep 9, 2025
- NCT07174830OfficialPhase 4Sep 6, 2025
- NCT06832917Sponsor investigatorPhase 3Mar 31, 2025
- NCT06832917Lead sponsorPhase 3Mar 31, 2025
- NCT06665048Sponsor investigatorN/ADec 1, 2024
- NCT06647940CollaboratorPhase 2Nov 1, 2024
- NCT06647732CollaboratorPhase 2Oct 25, 2024
- NCT06655662OfficialPhase 1Jun 12, 2024
- NCT06333821OfficialPhase 3Apr 1, 2024
- NCT06410833CollaboratorPhase 4Mar 9, 2024
- NCT06234072Sponsor investigatorPhase 2Feb 29, 2024
- NCT06234072Lead sponsorPhase 2Feb 29, 2024
Details
- Founded
- Shenzhen, CN Jan 1, 1983
- Last known activity
- Nov 30, 2025